Diabetic neuropathies

Diabetologia

Volumn 43, Issue 8, 2000, Pages 957-973

  Vinik, A I ^a   Park, T S ^a   Stansberry, K B ^a   Pittenger, G L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CARBAMAZEPINE; CLONIDINE; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUPHENAZINE; GABAPENTIN; GAMMA LINOLENIC ACID; IMMUNOGLOBULIN; INSULIN; LIDOCAINE; MEXILETINE; PHENOTHIAZINE DERIVATIVE; THIOCTIC ACID; TOLRESTAT; TRAMADOL; UNINDEXED DRUG; ZENARESTAT;

ALGORITHM; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ALDEHYDE REDUCTASE; ANIMALS; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; GAMMA-LINOLENIC ACID; GUANIDINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; THIOCTIC ACID;

EID: 0033837950     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051477     Document Type: Review

References (116)

1. Epidemiology of the complications of diabetes
2. Costs and duration of care for lower extremity ulcers in patients with diabetes
3. Assessment and management of foot disease in patients with diabetes
4. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population
5. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study
6. Diabetic neuropathy: Pathogenesis and therapy
7. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation
8. Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM
9. Mortality in diabetic patients with cardiovascular autonomic neuropathy
10. Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology
11. Progression of diabetic autonomic neuropathy
12. The effect of intensive treatment of diabetes on the development and progression of ling-term complications in insulin-dependent diabetes mellitus
13. The effect of intensive diabetes therapy on the development and progression of neuropathy
14. Somatic and autonomic nerve function during the first year after diagnosis of type 1 (insulin-dependent) diabetes
15. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus
16. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
17. Treatment of diabetic polyneuropathy (DPN) with recombinant human nerve growth factor (rhNGF)
18. The Rochester Diabetic Neuropathy Study: Design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests
19. Clinical Electromyelography: Nerve conduction studies
20. Quantitation of epidermal nerves in diabetic neuropathy
21. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies
22. The natural history of recently diagnosed autonomic neuropathy over a period of 2 years
23. Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment
24. Experimental diabetic neuropathy: An update
25. Diabetic neuropathies: Features and mechanisms
26. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy
27. Diabetic neuropathies
28. Autonomic Neuropathy
29. Entrapment neuropathies of the upper extremities
30. Epineurial microvasculitis in proximal diabetic neuropathy
31. Autoimmune mechanisms in the pathogenesis of diabetic neuropathy
32. Gangliosides and autoimmune neuropathies: Classification and clinical aspects of auto-immune neuropathies
33. Diabetic amyotrophy: Current concepts
34. Nerve biopsy findings in different patterns of proximal diabetic neuropathy
35. Successful treatment of neuropathies in patients with diabetes mellitus
36. Acute and remitting painful diabetic polyneuropathy: A comparison of peripheral nerve fibre pathology
37. Anti-ganglioside GM1 antibody and distalsymmetric 'diabetic polyneuropathy' with dominant motor features
38. Proximal diabetic neuropathy-response to immunotherapy
39. The clinical spectrum of diabetic neuropathy
40. Evaluation of somatic and autonomic small fibers neuropathy in diabetes
41. Epidermal nerve fiber density: Normative reference range and diagnostic efficiency
42. Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect
43. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis)
44. Diabetic neuropathic cachexia: The importance of positive recognition and early nutritional support
45. Small-fiber sensory neuropathies: Clinical course and neuropathology of idiopathic cases
46. Uncommon early-onset neuropathy in diabetic patients
47. Effects of autonomic neuropathy associated with diabetes mellitus on cardiovascular function
48. Impaired peripheral vasomotion in diabetes
49. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes
50. The effect of alpha-lipoic on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy
51. Diabetic autonomic neuropathy: What are the risks?
52. Early diagnosis of diabetic autonomic neuropathy: Present and future approaches
53. Detection, characterization and staging of polyneuropathy: Assessed in diabetes
54. Clinical aspects of diabetic neuropathies
55. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multi-centre randomized controlled trial (ALADIN Study)
56. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy
57. Diabetic neuropathies: An overview of clinical aspects
58. Quantitative measurement of cutaneous perception in diabetic neuropathy
59. Noninvasive exploration of cardiac autonomic neuropathy
60. Progressive polyradiculoneuropathy in diabetes: Correlation of variables and clinical outcome after immunotherapy
61. Painful sensory neuropathy: Prospective evaluation using skin biopsy
62. Autoimmune diabetic neuropathy
63. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973
64. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
65. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
66. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
67. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
68. A multicentre trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic neuropathy
69. Effect of aldose reductase inhibition on cardio-vascular reflex tests in patients with definite diabetic autonomic neuropathy
70. Effect of al-dose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
71. Aldose reductase inhibitor zopolrestat improves systolic function in diabetics
72. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial. Deutsche Kardiale Autonome Neuropathie
73. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy
74. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy
75. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy
76. Treatment of diabetic neuropathy with γ-linolenic acid
77. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats
78. Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozotocin-induced diabetes
79. PTB treatment restores joint mobility in a new model of diabetic cheirothropathy
80. Intravenous immunoglobulin therapy: Indication, potential side effects and treatment guidelines
81. Depletion of substance P and calcitonin gone-related peptide in sciatic nerve of rats with experimental diabetes: Effects of insulin and aldose reductase inhibition
82. Diabetes mellitus associated decrease in nerve growth factor levels is reversed by allogenetic pancreatic islet transplantation
83. Neuro-trophins and peripheral neuropathy
84. Neurotropic factors in the therapy of peripheral neuropathy
85. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
86. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis
87. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design
88. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy
89. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy
90. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
91. Effects of desipramine, amitryptylline and fluoxetine on pain in diabetic neuropathy
92. Anticonvulsant drugs for management of pain: A systematic review
93. Gabapentin in the treatment of painful diabetic neuropathy: A placebo controlled, double blind, crossover trial
94. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus
95. Neurontin (Gabapentin, GBP) improves quality of life (QOL) in patients with painful diabetic peripheral neuropathy
96. Treatment of neuropathic pain in a patient with diabetic neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar region
97. Calcitonin nasal spray for painful diabetic neuropathy
98. Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus
99. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial
100. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy
101. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study
102. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy
103. Effects of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy
104. Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus
105. Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension
106. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulin-dependent (type 2) diabetes mellitus
107. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis
108. Cisapride versus Placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: A double blind cross-over trial
109. Domperidone: A peripherally acting dopamine2-receptor antagonist
110. Domperidone in the management of symptoms of diabetic gastro-paresis: Efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group
111. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis
112. Erectile dysfunction in diabetes
113. Erectile dysfunction in diabetes: Pills for penile failure
114. Erectile dysfunction in patients with diabetes: Meta-analysis of 9 sildenafil (Viagra®) studies
115. Gustatory sweating in diabetes mellitus
116. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating